Gland Pharma · NSE: GLAND · BSE: 543245
Q1 FY26 results · Apr–Jun 2025
Gland Pharma reported revenue from operations of ₹1,505.62 crore (up 7.4% from Q1 FY25) and net profit of ₹215.48 crore (up 49.9% from Q1 FY25) for Q1 FY26 (Apr–Jun 2025), on a consolidated basis.
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,505.62 | 1,401.71 | +7.4% | 1,424.91 | +5.7% |
| Other income | 57.53 | 51.43 | +11.9% | 44.03 | +30.7% |
| Total income | 1,563.15 | 1,453.14 | +7.6% | 1,468.94 | +6.4% |
| Profit before tax | 312.74 | 218.25 | +43.3% | 288.33 | +8.5% |
| Net profit for the period | 215.48 | 143.76 | +49.9% | 186.54 | +15.5% |
| EPS, basic (₹) | 13.08 | 8.73 | +49.8% | 11.32 | +15.5% |
| Net margin (%) | 14.3 | 10.3 | 13.1 |
| Item | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,038.84 | 1,012.02 | +2.6% | 1,030.35 | +0.8% |
| Other income | 54.74 | 48.49 | +12.9% | 43.72 | +25.2% |
| Total income | 1,093.58 | 1,060.51 | +3.1% | 1,074.07 | +1.8% |
| Profit before tax | 362.38 | 300.31 | +20.7% | 391.32 | −7.4% |
| Net profit for the period | 269.26 | 222.92 | +20.8% | 290.00 | −7.2% |
| EPS, basic (₹) | 16.34 | 13.53 | +20.8% | 17.60 | −7.2% |
| Net margin (%) | 25.9 | 22.0 | 28.1 |
Consolidated
- Filed with BSE
- 05 Aug 2025, 18:00 IST
- Board meeting
- 05 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2025, 18:00 IST
- Board meeting
- 05 Aug 2025
- Period
- 01 Apr 2025 to 30 Jun 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE